Gilead Sciences Overview

  • Founded
  • 1987
Founded
  • Status
  • Public
  • Employees
  • 11,800
Employees
  • Stock Symbol
  • GILD
Stock Symbol
  • Investments
  • 47
  • Share Price
  • $59.89
  • (As of Monday Closing)

Gilead Sciences General Information

Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Contact Information

Website
Formerly Known As
Oligogen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 333 Lakeside Drive
  • Foster City, CA 94404
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gilead Sciences Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$59.89 $60.11 $57.04 - $85.97 $75.3B 1.25B 9.4M $0.99

Gilead Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 84,525,843 84,073,162 79,912,907 94,865,111
Revenue 23,147,000 22,449,000 22,127,000 26,107,000
EBITDA 4,119,000 7,559,000 10,305,000 15,933,000
Net Income 1,268,000 5,386,000 5,455,000 4,628,000
Total Assets 60,878,000 61,627,000 63,675,000 70,283,000
Total Debt 29,290,000 24,593,000 27,322,000 33,542,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gilead Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portf
Biotechnology
Foster City, CA
11,800 As of 2019
00.000
0&0

00000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
000000000000000
Basel, Switzerland
000000 As of 0000
000000000000

0000000

lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
000000000000000
Boston, MA
0000 As of 0000
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gilead Sciences Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland 000000 000000000000
0000000 Formerly VC-backed Boston, MA 0000 000000&0
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
00000 & 00. Corporation Kenilworth, NJ 00000 00000000
You’re viewing 5 of 62 competitors. Get the full list »

Gilead Sciences Executive Team (49)

Name Title Board Seat Contact Info
Daniel O'Day Chief Executive Officer, Chairman of the Board & Director
Christi Shaw Chief Executive Officer
Andrew Dickinson Chief Financial Officer, Finance & Executive Vice President
Wim Eeraerts General Manager - Belgium & Luxemburg
Diane Wilfong Chief Accounting Officer, Accounting & Controller, Finance
You’re viewing 5 of 49 executive team members. Get the full list »

Gilead Sciences Board Members (23)

Name Representing Role Since
Anthony Welters JD Self Board Member 000 0000
Daniel O'Day Gilead Sciences Chief Executive Officer, Chairman of the Board & Director 000 0000
Harish Manwani Self Board Member 000 0000
Jacqueline Barton Self Board Member 000 0000
Javier Rodriguez Self Board Member 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Gilead Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gilead Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.

Request a free trial

Gilead Sciences Investments & Acquisitions (47)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 23-Oct-2020 000000000000000000 0000 Drug Discovery 000000 0'000
000000 13-Oct-2020 00000 00000 00 0000 Decision/Risk Analysis 0000000 000000000
00000 000000000000 17-Aug-2020 00000 00000 00 0000 Drug Discovery
000000 00000000000 21-Jul-2020 000000000000000000 00000 Biotechnology 000000 0'000
Glympse Bio 15-Jul-2020 Early Stage VC 000.00 Diagnostic Equipment
You’re viewing 5 of 47 investments and acquisitions. Get the full list »

Gilead Sciences Subsidiaries (3)

Company Name Industry Location Founded
Kite Pharma Biotechnology Santa Monica, CA 2009
000000 Pharmaceuticals Westminster, CO 0000
000000000000 Drug Discovery Morris Plains, NJ 0000
To view Gilead Sciences’s complete subsidiaries history, request access »

Gilead Sciences Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 00000000 01-Mar-2019 00000 00000 00 00000 Completed
  • 21 buyers
0000000 000000 11-Dec-2017 00000 00000 00 000.00 Completed
  • 9 buyers
0000000 0000000000 17-Mar-2014 00000 00000 00 0000 Completed
  • 12 buyers
000000000 03-Dec-2004 00000 00000 00 000 Completed
  • 8 buyers
TriPharm Services 16-Jan-2003 Merger/Acquisition 00000 Completed
To view Gilead Sciences’s complete exits history, request access »